Olmetec and Fluid retention - a phase IV clinical study of FDA data

Summary:

Fluid retention is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are male, 60+ old, also take Norvasc, and have Hypothyroidism.

The phase IV clinical study analyzes which people have Fluid retention when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Fluid retention?

Fluid retention (an abnormal accumulation of fluid in the blood) is found to be associated with 1,703 drugs and 2,443 conditions by eHealthMe. Check the latest studies of Fluid retention.

On May, 02, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 20 people (0.26%) have Fluid retention.

Among these 20 people:

What is the gender of people who have Fluid retention when taking Olmetec? *

female: 38.89 %
male: 61.11 %

What is the age of people who have Fluid retention when taking Olmetec? *

What are other drugs people take besides Olmetec? *

What are other side effects people have besides Fluid retention? *

Headache (pain in head): 9 people, 45.00%
Cellulitis (infection under the skin): 7 people, 35.00%
Pain: 7 people, 35.00%
Peripheral Swelling: 6 people, 30.00%
Fatigue (feeling of tiredness): 6 people, 30.00%
Drowsiness: 6 people, 30.00%
Fall: 6 people, 30.00%
Joint Pain: 5 people, 25.00%
Oedema Peripheral (superficial swelling): 5 people, 25.00%
Nausea (feeling of having an urge to vomit): 5 people, 25.00%

What are the existing conditions these people have? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 25.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 20.00%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 15.00%
Growth Hormone Deficiency: 3 people, 15.00%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 3 people, 15.00%
Ischaemia (insufficient supply of blood to an organ, usually due to a blocked artery): 2 people, 10.00%
Diabetes: 2 people, 10.00%
Gastritis (inflammation of stomach): 2 people, 10.00%
Sleep Disorder: 2 people, 10.00%
Joint Pain: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Fluid retention?

- Check whether Fluid retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Fluid retention treatments and more:

Fluid retention (79,660 reports)

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid retention:

Fluid retention (1,703 drugs)

Browse all the conditions that are associated with Fluid retention:

Fluid retention (2,443 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.